Health Care·Life Sciences Tools & Services·$174.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.31 | N/A | +1.61% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $2.31 | N/A | +1.61% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting ongoing efforts to enhance operational efficiency. They emphasized their commitment to innovation.
We are pleased with our performance this quarter.
Our focus remains on driving innovation and efficiency.
Thermo Fisher Scientific's better-than-expected EPS indicates strong performance in managing costs and driving profitability. The stock rose by 2.72% following the announcement, reflecting investor confidence in the company's operational strategies. However, the lack of revenue data and forward guidance leaves some uncertainty about future growth prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
STATE STR CORP
Oct 23, 2017